Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MANISH SHARMA

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1790819332
CMS profile
1126262
Location
GRAND RAPIDS, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$185.35

5 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $185.35 5

By paying entity

PY2020 · entire year · sorted by reported total

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MANISH SHARMA

NPI 1790819332 · CMS profile ID 1126262

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

GRAND RAPIDS, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1790819332?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MANISH SHARMA, NPI 1790819332, CMS profile ID 1126262. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1790819332?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). MANISH SHARMA, NPI 1790819332, CMS profile ID 1126262. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1790819332?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
MANISH SHARMA, NPI 1790819332, CMS profile ID 1126262, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1790819332?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

5 matching records · $185.35 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 5 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–5 of 5.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Adaptive Biotechnologies Corporation $20.5404/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751728339 CMS
Jazz Pharmaceuticals Inc. $17.7403/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744453069 CMS
Bayer HealthCare Pharmaceuticals Inc. $13.9703/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 713650555 CMS
Bayer HealthCare Pharmaceuticals Inc. $18.9802/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 713644195 CMS
Merck Sharp & Dohme Corporation $114.1201/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747615597 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $659.76 21
PY2020 $185.35 5
PY2021 $23.93 1
PY2022 $558.49 34
PY2023 $1,123.71 47
PY2024 $773.90 11
PY2025 $1,855.50 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $373.20 2
PY2025 Principal investigator $4,235,582.65 823
PY2024 Recipient $4,269.33 9
PY2024 Principal investigator $3,811,534.65 643
PY2023 Recipient $3,810.00 6
PY2023 Principal investigator $3,149,687.09 471
PY2022 Principal investigator $3,302,171.04 339
PY2021 Recipient $7,293.02 4
PY2021 Principal investigator $2,076,760.51 208
PY2020 Recipient $7,900.00 2
PY2020 Principal investigator $1,132,655.23 78
PY2019 Principal investigator $1,305,040.24 61

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

339 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,939.26 12/31/2022 Non-covered Recipient Entity
CANCER AND HEMATOLOGY
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation No dispute reported 06/30/2026 914602557
Principal investigator 1 Exelixis Inc. $994.50 12/28/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943765055
Principal investigator 1 MACROGENICS, INC. $153.01 12/27/2022 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 936962053
Principal investigator 1 ABBVIE INC. $50.00 12/22/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889826725
Principal investigator 1 ABBVIE INC. $50.00 12/22/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889826797
Principal investigator 1 ABBVIE INC. $50.00 12/22/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889826799
Principal investigator 1 ABBVIE INC. $50.00 12/22/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889826897
Principal investigator 1 ABBVIE INC. $50.00 12/22/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889826917
Principal investigator 1 PFIZER INC. $12,791.42 12/22/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949767561
Principal investigator 1 PFIZER INC. $256.50 12/21/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND EXPANSION STUDY OF PF07265028 AS A SINGLE AGENT AND IN COMBINATION WITH SASANLIMAB EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07265028 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 949769697
Principal investigator 1 PFIZER INC. $5,817.18 12/19/2022 Non-covered Recipient Entity
START Midwest
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 949761841
Principal investigator 1 PFIZER INC. $14,284.20 12/19/2022 Non-covered Recipient Entity
START Midwest
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949762363
Principal investigator 1 ABBVIE INC. $2,448.56 12/16/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889825949
Principal investigator 1 ABBVIE INC. $1,371.60 12/16/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889825951
Principal investigator 1 ABBVIE INC. $2,267.66 12/16/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889825953
Principal investigator 1 ABBVIE INC. $2,267.66 12/16/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889825955
Principal investigator 1 ABBVIE INC. $2,448.56 12/16/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889825965
Principal investigator 1 ABBVIE INC. $2,462.06 12/16/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889825967
Principal investigator 1 ABBVIE INC. $4,291.31 12/16/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889825969
Principal investigator 1 ABBVIE INC. $2,367.56 12/16/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889825971
Principal investigator 1 ABBVIE INC. $1,979.10 12/16/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889825973
Principal investigator 1 ABBVIE INC. $2,267.66 12/16/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889825983
Principal investigator 1 ABBVIE INC. $3,589.31 12/16/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889826043
Principal investigator 1 ABBVIE INC. $2,367.56 12/16/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889826045
Principal investigator 1 ABBVIE INC. $1,930.16 12/16/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889826047
Principal investigator 1 ABBVIE INC. $2,732.06 12/16/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889826085
Principal investigator 1 ABBVIE INC. $1,371.60 12/16/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889826101
Principal investigator 1 ABBVIE INC. $1,979.10 12/16/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889826115
Principal investigator 1 ABBVIE INC. $100.00 12/16/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889826127
Principal investigator 1 ABBVIE INC. $2,732.06 12/16/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889826139
Principal investigator 1 ABBVIE INC. $1,371.60 12/16/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889826153
Principal investigator 1 ABBVIE INC. $2,362.16 12/16/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889826155
Principal investigator 1 ABBVIE INC. $2,362.16 12/16/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889826157
Principal investigator 1 ABBVIE INC. $2,267.66 12/16/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889826159
Principal investigator 1 ABBVIE INC. $1,930.16 12/16/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889826161
Principal investigator 1 ABBVIE INC. $4,291.31 12/16/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889826183
Principal investigator 1 ABBVIE INC. $1,371.60 12/16/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889826185
Principal investigator 1 ABBVIE INC. $100.00 12/16/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889826187
Principal investigator 1 ABBVIE INC. $500.85 12/16/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889826189
Principal investigator 1 ABBVIE INC. $2,543.06 12/16/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889826231
Principal investigator 1 ABBVIE INC. $2,462.06 12/16/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889826233
Principal investigator 1 ABBVIE INC. $3,589.31 12/16/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889826235
Principal investigator 1 Merck Sharp & Dohme LLC $117,000.00 12/15/2022 Non-covered Recipient Entity
START MIDWEST
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX 106 and INBRX-106 in Combination with Pembrolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 940418469
Principal investigator 1 PFIZER INC. $9.00 12/15/2022 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949761125
Principal investigator 1 PFIZER INC. $128.25 12/14/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949767383
Principal investigator 1 PFIZER INC. $26,747.44 12/12/2022 Non-covered Recipient Entity
START Midwest
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949762173
Principal investigator 1 Exelixis Inc. $2,751.30 12/09/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943764865
Principal investigator 1 Exelixis Inc. $517.05 12/09/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943764867
Principal investigator 1 Exelixis Inc. $148.50 12/09/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943764889
Principal investigator 1 Exelixis Inc. $1,000.00 12/09/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943764891
Principal investigator 1 Exelixis Inc. $150.00 12/09/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943764893
Principal investigator 1 Exelixis Inc. $675.00 12/09/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943764895
Principal investigator 1 Exelixis Inc. $58.05 12/07/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943764839
Principal investigator 1 Exelixis Inc. $1,989.90 12/07/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943764841
Principal investigator 1 Exelixis Inc. $982.80 12/07/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943764843
Principal investigator 1 PFIZER INC. $17,335.36 12/07/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949767559
Principal investigator 1 PFIZER INC. $985.50 12/07/2022 Non-covered Recipient Entity
START Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 949769673
Principal investigator 1 Merck Sharp & Dohme LLC $39,000.00 12/05/2022 Non-covered Recipient Entity
START MIDWEST
A Phase 1 Open-label Dose Escalation Trial of BDB018 in Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors No dispute reported 06/30/2026 940392341
Principal investigator 1 Merck Sharp & Dohme LLC $71,000.00 11/30/2022 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
A Phase 1,1b Dose Escalation,Expansion Study of NGM438 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 940392645
Principal investigator 1 PFIZER INC. $25,999.94 11/30/2022 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949761127
Principal investigator 1 PFIZER INC. $18.00 11/30/2022 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949761313
Principal investigator 1 PFIZER INC. $32.40 11/30/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949779069
Principal investigator 1 PFIZER INC. $35,317.55 11/24/2022 Non-covered Recipient Entity
START Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 949778959
Principal investigator 1 PFIZER INC. $25,521.02 11/24/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949778981
Principal investigator 1 PFIZER INC. $11,933.67 11/24/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949779071
Principal investigator 1 PFIZER INC. $5,817.18 11/21/2022 Non-covered Recipient Entity
START Midwest
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 949762175
Principal investigator 1 PFIZER INC. $17,855.25 11/21/2022 Non-covered Recipient Entity
START Midwest
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949762365
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 11/16/2022 Non-covered Recipient Entity
MULTIPLE DOCTORS
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 943945393
Principal investigator 1 Exelixis Inc. $211,960.06 11/11/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943764739
Principal investigator 1 ABBVIE INC. $3,500.00 11/10/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889820457
Principal investigator 1 PFIZER INC. $8,293.78 11/10/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949779017
Principal investigator 1 PFIZER INC. $23,637.26 11/05/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949779013
Principal investigator 1 Exelixis Inc. $1,135.00 11/04/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943764487
Principal investigator 1 Exelixis Inc. $2,748.60 11/04/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943764489
Principal investigator 1 GlaxoSmithKline, LLC. $6,820.00 11/04/2022 Non-covered Recipient Entity
MULTIPLE DOCTORS
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 943945403
Principal investigator 1 PFIZER INC. $6,655.00 11/04/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND EXPANSION STUDY OF PF07265028 AS A SINGLE AGENT AND IN COMBINATION WITH SASANLIMAB EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07265028 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 949778983
Principal investigator 1 PFIZER INC. $15,977.25 11/04/2022 Non-covered Recipient Entity
START Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 949779015
Principal investigator 1 PFIZER INC. $1,085.00 10/28/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949787627
Principal investigator 1 PFIZER INC. $7,142.10 10/27/2022 Non-covered Recipient Entity
START Midwest
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949761655
Principal investigator 1 PFIZER INC. $4,834.10 10/25/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949787719
Principal investigator 1 PFIZER INC. $1,066.10 10/25/2022 Non-covered Recipient Entity
START Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 949792965
Principal investigator 1 PFIZER INC. $2,555.89 10/25/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949794329
Principal investigator 1 PFIZER INC. $5,817.18 10/24/2022 Non-covered Recipient Entity
START Midwest
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 949761129
Principal investigator 1 PFIZER INC. $26,621.41 10/22/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949787483
Principal investigator 1 Merck Sharp & Dohme LLC $63,900.00 10/20/2022 Non-covered Recipient Entity
START MIDWEST
A Phase 1,1b Dose Escalation,Expansion Study of NGM831 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 940392595
Principal investigator 1 Exelixis Inc. $16,495.51 10/17/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943764465
Principal investigator 1 Exelixis Inc. $675.00 10/17/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943764473
Principal investigator 1 MACROGENICS, INC. $75.01 10/17/2022 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 936960059
Principal investigator 1 PFIZER INC. $18.00 10/14/2022 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949761657
Principal investigator 1 PFIZER INC. $25,000.00 10/14/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07062119 IN PATIENTS WITH ADVANCED GASTROINTESTINAL TUMORS No dispute reported 06/30/2026 949794561
Principal investigator 1 PFIZER INC. $2,555.89 10/12/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949794591
Principal investigator 1 Exelixis Inc. $1,000.00 10/10/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943764383
Principal investigator 1 Exelixis Inc. $750.00 10/10/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943764385
Principal investigator 1 PFIZER INC. $26,747.44 10/10/2022 Non-covered Recipient Entity
START Midwest
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949761315
Principal investigator 1 PFIZER INC. $14,284.20 10/10/2022 Non-covered Recipient Entity
START Midwest
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949761653
Principal investigator 1 PFIZER INC. $8,290.18 10/08/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949787229
Principal investigator 1 PFIZER INC. $17,188.20 10/07/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949787625
Principal investigator 1 PFIZER INC. $420.25 10/07/2022 Non-covered Recipient Entity
START Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 949792967
Principal investigator 1 PFIZER INC. $4,725.00 10/07/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND EXPANSION STUDY OF PF07265028 AS A SINGLE AGENT AND IN COMBINATION WITH SASANLIMAB EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07265028 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 949794357
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $30,194.00 10/06/2022 Non-covered Recipient Entity
Start Midwest
PhI II TIGIT BiSpec combo Nivo NG CTLA4 safety & NSCLC expansion - A Phase 1b/2 Study of BMS-986442 in Combination with Nivolumab or Nivolumab and Chemotherapies in Participants with Advanced Solid Tumors and Non-small Cell Lung Cancer No dispute reported 06/30/2026 933198939
Principal investigator 1 Exelixis Inc. $2,751.30 09/28/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943762907
Principal investigator 1 Exelixis Inc. $1,012.50 09/28/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943762909
Principal investigator 1 Exelixis Inc. $6,750.00 09/28/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943762983
Principal investigator 1 Exelixis Inc. $969.00 09/28/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943762985
Principal investigator 1 Exelixis Inc. $112.05 09/28/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943762987
Principal investigator 1 PFIZER INC. $6,786.71 09/26/2022 Non-covered Recipient Entity
START Midwest
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 949760279
Principal investigator 1 PFIZER INC. $45,505.81 09/23/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949792787
Principal investigator 1 PFIZER INC. $25,844.42 09/22/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949792781
Principal investigator 1 MACROGENICS, INC. $407.03 09/20/2022 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 936959603
Principal investigator 1 Exelixis Inc. $74.25 09/16/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943762939
Principal investigator 1 Exelixis Inc. $688.50 09/16/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943762941
Principal investigator 1 Exelixis Inc. $7,420.00 09/16/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943762943
Principal investigator 1 Exelixis Inc. $112.05 09/16/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943762945
Principal investigator 1 GlaxoSmithKline, LLC. $50.00 09/16/2022 Non-covered Recipient Entity
MULTIPLE DOCTORS
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 943945391
Principal investigator 1 Exelixis Inc. $35,340.57 09/14/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943762827
Principal investigator 1 PFIZER INC. $21.60 09/14/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949792783
Principal investigator 1 PFIZER INC. $40,121.16 09/06/2022 Non-covered Recipient Entity
START Midwest
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949761837
Principal investigator 1 PFIZER INC. $5,713.68 09/06/2022 Non-covered Recipient Entity
START Midwest
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949761839
Principal investigator 1 PFIZER INC. $2,269.30 09/02/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949792667
Principal investigator 1 PFIZER INC. $3,130.50 09/02/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949792785
Principal investigator 1 PFIZER INC. $4,975.70 09/02/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND EXPANSION STUDY OF PF07265028 AS A SINGLE AGENT AND IN COMBINATION WITH SASANLIMAB EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07265028 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 949792977
Principal investigator 1 MACROGENICS, INC. $344.59 08/31/2022 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 936959149
Principal investigator 1 PFIZER INC. $3,389.50 08/26/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949802573
Principal investigator 1 MACROGENICS, INC. $1,800.00 08/25/2022 Non-covered Recipient Entity
CANCER AND HEMATOLOGY CENTERS
COMBINATION MARGETUXIMAB, INCMGA00012, MGD013, AND CHEMOTHERAPY PHASE 2 3 TRIAL IN HER2 GASTRIC GEJ CANCER MAHOGANY No dispute reported 06/30/2026 936959031
Principal investigator 1 Merck Sharp & Dohme LLC $56,800.00 08/25/2022 Non-covered Recipient Entity
START MIDWEST
A Phase 1,2 Dose Escalation,Expansion Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies No dispute reported 06/30/2026 940392333
Principal investigator 1 PFIZER INC. $3,071.85 08/24/2022 Non-covered Recipient Entity
START Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 949801769
Principal investigator 1 PFIZER INC. $28,308.16 08/24/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949802971
Principal investigator 1 PFIZER INC. $44,520.66 08/24/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949803245
Principal investigator 1 ABBVIE INC. $50.00 08/22/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889807299
Principal investigator 1 ABBVIE INC. $500.00 08/22/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889807313
Principal investigator 1 ABBVIE INC. $50.00 08/22/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889807315
Principal investigator 1 ABBVIE INC. $50.00 08/22/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889807317
Principal investigator 1 ABBVIE INC. $50.00 08/22/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889807333
Principal investigator 1 GlaxoSmithKline, LLC. $50.00 08/19/2022 Non-covered Recipient Entity
MULTIPLE DOCTORS
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 943945401
Principal investigator 1 MACROGENICS, INC. $1,445.72 08/12/2022 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 936958819
Principal investigator 1 MACROGENICS, INC. $615.20 08/12/2022 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 936958825
Principal investigator 1 MACROGENICS, INC. $1,015.08 08/12/2022 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 936958831
Principal investigator 1 PFIZER INC. $47,394.14 08/05/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949801433
Principal investigator 1 PFIZER INC. $9,704.00 08/05/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND EXPANSION STUDY OF PF07265028 AS A SINGLE AGENT AND IN COMBINATION WITH SASANLIMAB EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07265028 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 949801839
Principal investigator 1 PFIZER INC. $28,209.55 08/05/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949802463
Principal investigator 1 PFIZER INC. $47,088.13 08/05/2022 Non-covered Recipient Entity
START Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 949802725
Principal investigator 1 PFIZER INC. $98,900.57 08/05/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949804281
Principal investigator 1 Exelixis Inc. $739.50 08/03/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943762507
Principal investigator 1 ABBVIE INC. $1,371.60 08/01/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889802781
Principal investigator 1 ABBVIE INC. $4,291.31 08/01/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889802783
Principal investigator 1 ABBVIE INC. $2,543.06 08/01/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889802799
Principal investigator 1 ABBVIE INC. $2,362.16 08/01/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889802801
Principal investigator 1 ABBVIE INC. $1,979.10 08/01/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889802803
Principal investigator 1 ABBVIE INC. $1,930.16 08/01/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889802805
Principal investigator 1 ABBVIE INC. $2,732.06 08/01/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889802807
Principal investigator 1 ABBVIE INC. $3,589.31 08/01/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889802815
Principal investigator 1 ABBVIE INC. $1,930.16 08/01/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889802817
Principal investigator 1 ABBVIE INC. $2,267.66 08/01/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889802819
Principal investigator 1 ABBVIE INC. $1,979.10 08/01/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889802821
Principal investigator 1 ABBVIE INC. $2,267.66 08/01/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889802823
Principal investigator 1 ABBVIE INC. $2,543.06 08/01/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889802829
Principal investigator 1 ABBVIE INC. $1,371.60 08/01/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889802831
Principal investigator 1 ABBVIE INC. $3,589.31 08/01/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889802833
Principal investigator 1 ABBVIE INC. $2,551.16 08/01/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889802835
Principal investigator 1 ABBVIE INC. $4,291.31 08/01/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889802845
Principal investigator 1 ABBVIE INC. $2,362.16 08/01/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889802849
Principal investigator 1 ABBVIE INC. $2,267.66 08/01/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889802869
Principal investigator 1 ABBVIE INC. $2,267.66 08/01/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889802871
Principal investigator 1 PFIZER INC. $969.53 08/01/2022 Non-covered Recipient Entity
START Midwest
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 949760277
Principal investigator 1 PFIZER INC. $13,573.42 08/01/2022 Non-covered Recipient Entity
START Midwest
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 949761771
Principal investigator 1 PFIZER INC. $2,908.59 08/01/2022 Non-covered Recipient Entity
START Midwest
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 949761967
Principal investigator 1 GlaxoSmithKline, LLC. $2,728.00 07/29/2022 Non-covered Recipient Entity
MULTIPLE DOCTORS
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 943945417
Principal investigator 1 Exelixis Inc. $622.35 07/22/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943762487
Principal investigator 1 Exelixis Inc. $2,326.05 07/22/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943762489
Principal investigator 1 Exelixis Inc. $1,000.00 07/22/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943762491
Principal investigator 1 Exelixis Inc. $715.50 07/22/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943763507
Principal investigator 1 PFIZER INC. $46,869.32 07/21/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949806133
Principal investigator 1 PFIZER INC. $3,015.22 07/21/2022 Non-covered Recipient Entity
SMART Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 949806137
Principal investigator 1 PFIZER INC. $17,720.90 07/21/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND EXPANSION STUDY OF PF07265028 AS A SINGLE AGENT AND IN COMBINATION WITH SASANLIMAB EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07265028 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 949806765
Principal investigator 1 ABBVIE INC. $1,550.00 07/18/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889801471
Principal investigator 1 Exelixis Inc. $2,894.60 07/18/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943762331
Principal investigator 1 GlaxoSmithKline, LLC. $104,214.00 07/18/2022 Non-covered Recipient Entity
MULTIPLE DOCTORS
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 943945411
Principal investigator 1 MACROGENICS, INC. $32,095.46 07/18/2022 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 936958515
Principal investigator 1 MACROGENICS, INC. $13,657.64 07/18/2022 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 936958521
Principal investigator 1 MACROGENICS, INC. $22,535.11 07/18/2022 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 936958527
Principal investigator 1 PFIZER INC. $51,999.88 07/18/2022 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949761767
Principal investigator 1 MACROGENICS, INC. $12,986.10 07/12/2022 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 936958445
Principal investigator 1 MACROGENICS, INC. $5,526.00 07/12/2022 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 936958451
Principal investigator 1 MACROGENICS, INC. $9,117.90 07/12/2022 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 936958455
Principal investigator 1 PFIZER INC. $969.53 07/11/2022 Non-covered Recipient Entity
START Midwest
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 949761769
Principal investigator 1 PFIZER INC. $2,484.00 07/09/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949806135
Principal investigator 1 PFIZER INC. $21,744.81 07/09/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949806573
Principal investigator 1 PFIZER INC. $17,688.38 07/09/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949807101
Principal investigator 1 GlaxoSmithKline, LLC. $45.00 07/08/2022 Non-covered Recipient Entity
MULTIPLE DOCTORS
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 943945397
Principal investigator 1 GlaxoSmithKline, LLC. $2,700.00 07/08/2022 Non-covered Recipient Entity
MULTIPLE DOCTORS
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 943945405
Principal investigator 1 Exelixis Inc. $1,224.00 07/06/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943762275
Principal investigator 1 Exelixis Inc. $535.95 07/06/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943762277
Principal investigator 1 Exelixis Inc. $436.05 07/06/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943762279
Principal investigator 1 PFIZER INC. $969.53 07/05/2022 Non-covered Recipient Entity
START Midwest
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 949760275
Principal investigator 1 Exelixis Inc. $30,264.30 06/24/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943760723
Principal investigator 1 PFIZER INC. $45,073.52 06/24/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949814153
Principal investigator 1 PFIZER INC. $7,560.68 06/22/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949810377
Principal investigator 1 PFIZER INC. $18,884.56 06/22/2022 Non-covered Recipient Entity
SMART Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 949814155
Principal investigator 1 PFIZER INC. $45.00 06/21/2022 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949814115
Principal investigator 1 PFIZER INC. $4,847.65 06/21/2022 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949814119
Principal investigator 1 Exelixis Inc. $453.60 06/20/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943760693
Principal investigator 1 Exelixis Inc. $1,386.45 06/20/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943760695
Principal investigator 1 Exelixis Inc. $3,299.40 06/20/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943760697
Principal investigator 1 Exelixis Inc. $8,378.57 06/20/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943760705
Principal investigator 1 Exelixis Inc. $189.00 06/20/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943760707
Principal investigator 1 Exelixis Inc. $1,012.50 06/20/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943760709
Principal investigator 1 MACROGENICS, INC. $286.00 06/13/2022 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 936957941
Principal investigator 1 PFIZER INC. $28,634.21 06/04/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949814341
Principal investigator 1 PFIZER INC. $17,247.27 06/03/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949810375
Principal investigator 1 PFIZER INC. $17,965.10 06/03/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND EXPANSION STUDY OF PF07265028 AS A SINGLE AGENT AND IN COMBINATION WITH SASANLIMAB EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07265028 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 949814343
Principal investigator 1 PFIZER INC. $12,251.94 05/24/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949748327
Principal investigator 1 GlaxoSmithKline, LLC. $7,100.00 05/23/2022 Non-covered Recipient Entity
MULTIPLE DOCTORS
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 943945389
Principal investigator 1 GlaxoSmithKline, LLC. $2,217.00 05/23/2022 Non-covered Recipient Entity
MULTIPLE DOCTORS
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 943945409
Principal investigator 1 PFIZER INC. $4,847.65 05/23/2022 Non-covered Recipient Entity
START Midwest
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 949814117
Principal investigator 1 PFIZER INC. $1,397.25 05/21/2022 Non-covered Recipient Entity
SMART Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 949748331
Principal investigator 1 ABBVIE INC. $935.00 05/19/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889792379
Principal investigator 1 PFIZER INC. $90.00 05/19/2022 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949814827
Principal investigator 1 Exelixis Inc. $16,210.80 05/16/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943760367
Principal investigator 1 MACROGENICS, INC. $4,594.97 05/16/2022 Non-covered Recipient Entity
START MIDWEST LLC
MGC018 WITH OR WITHOUT MGA012 IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 936957591
Principal investigator 1 MACROGENICS, INC. $1,955.31 05/16/2022 Non-covered Recipient Entity
START MIDWEST LLC
MGC018 WITH OR WITHOUT MGA012 IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 936957597
Principal investigator 1 MACROGENICS, INC. $3,226.25 05/16/2022 Non-covered Recipient Entity
START MIDWEST LLC
MGC018 WITH OR WITHOUT MGA012 IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 936957603
Principal investigator 1 PFIZER INC. $7,756.24 05/16/2022 Non-covered Recipient Entity
START Midwest
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949810391
Principal investigator 1 Exelixis Inc. $1,020.60 05/11/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943760347
Principal investigator 1 Exelixis Inc. $1,020.60 05/11/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943760349
Principal investigator 1 Exelixis Inc. $2,751.30 05/11/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943760351
Principal investigator 1 Exelixis Inc. $42.15 05/11/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943760353
Principal investigator 1 PFIZER INC. $25,000.00 05/07/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949748321
Principal investigator 1 PFIZER INC. $20,140.86 05/06/2022 Non-covered Recipient Entity
SMART Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 949747869
Principal investigator 1 PFIZER INC. $1,956.50 05/06/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949747875
Principal investigator 1 PFIZER INC. $476.00 05/06/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949748795
Principal investigator 1 Exelixis Inc. $382.50 04/22/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943760233
Principal investigator 1 Exelixis Inc. $137.30 04/22/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943760235
Principal investigator 1 Exelixis Inc. $2,751.30 04/22/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943760237
Principal investigator 1 Exelixis Inc. $1,053.00 04/22/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943760239
Principal investigator 1 ABBVIE INC. $1,395.57 04/21/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889788011
Principal investigator 1 PFIZER INC. $2,152.00 04/21/2022 Non-covered Recipient Entity
SMART Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 949817699
Principal investigator 1 Exelixis Inc. $21,531.89 04/15/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943760141
Principal investigator 1 MACROGENICS, INC. $328.00 04/13/2022 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 936957161
Principal investigator 1 PFIZER INC. $45.00 04/13/2022 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949814539
Principal investigator 1 PFIZER INC. $1,939.06 04/12/2022 Non-covered Recipient Entity
START Midwest
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 949814645
Principal investigator 1 Exelixis Inc. $5,502.60 04/08/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943760097
Principal investigator 1 Exelixis Inc. $2,751.30 04/08/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943760099
Principal investigator 1 PFIZER INC. $24,000.00 04/08/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND EXPANSION STUDY OF PF07265028 AS A SINGLE AGENT AND IN COMBINATION WITH SASANLIMAB EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07265028 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 949816453
Principal investigator 1 PFIZER INC. $2,325.00 04/08/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949817371
Principal investigator 1 PFIZER INC. $21,492.00 04/08/2022 Non-covered Recipient Entity
SMART Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 949817701
Principal investigator 1 PFIZER INC. $55,949.64 04/08/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949817703
Principal investigator 1 MACROGENICS, INC. $16,284.72 04/05/2022 Non-covered Recipient Entity
START MIDWEST LLC
MGC018 WITH OR WITHOUT MGA012 IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 936957097
Principal investigator 1 MACROGENICS, INC. $6,929.67 04/05/2022 Non-covered Recipient Entity
START MIDWEST LLC
MGC018 WITH OR WITHOUT MGA012 IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 936957103
Principal investigator 1 MACROGENICS, INC. $11,433.96 04/05/2022 Non-covered Recipient Entity
START MIDWEST LLC
MGC018 WITH OR WITHOUT MGA012 IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 936957109
Principal investigator 1 Exelixis Inc. $297.00 03/25/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766871
Principal investigator 1 Exelixis Inc. $8,347.50 03/25/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766873
Principal investigator 1 Exelixis Inc. $414.45 03/25/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766875
Principal investigator 1 Exelixis Inc. $946.35 03/25/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766877
Principal investigator 1 GlaxoSmithKline, LLC. $2,127.50 03/25/2022 Non-covered Recipient Entity
MULTIPLE DOCTORS
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 943945399
Principal investigator 1 GlaxoSmithKline, LLC. $2,409.75 03/25/2022 Non-covered Recipient Entity
MULTIPLE DOCTORS
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 943945413
Principal investigator 1 GlaxoSmithKline, LLC. $7,870.50 03/25/2022 Non-covered Recipient Entity
MULTIPLE DOCTORS
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 943945415
Principal investigator 1 ABBVIE INC. $329.41 03/24/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889782531
Principal investigator 1 PFIZER INC. $2,115.79 03/24/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949824611
Principal investigator 1 Exelixis Inc. $586.50 03/23/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943767067
Principal investigator 1 Exelixis Inc. $750.00 03/23/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943767069
Principal investigator 1 Exelixis Inc. $1,687.50 03/23/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943767071
Principal investigator 1 PFIZER INC. $16,956.48 03/23/2022 Non-covered Recipient Entity
SMART Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 949824043
Principal investigator 1 MACROGENICS, INC. $7,257.84 03/22/2022 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 936956897
Principal investigator 1 MACROGENICS, INC. $3,088.44 03/22/2022 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 936956903
Principal investigator 1 MACROGENICS, INC. $5,095.93 03/22/2022 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 936956909
Principal investigator 1 PFIZER INC. $2,908.59 03/21/2022 Non-covered Recipient Entity
START Midwest
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 949813849
Principal investigator 1 PFIZER INC. $1,652.00 03/16/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949824605
Principal investigator 1 Exelixis Inc. $35,007.12 03/14/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766901
Principal investigator 1 Exelixis Inc. $152.55 03/14/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766905
Principal investigator 1 Exelixis Inc. $88.70 03/14/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766907
Principal investigator 1 Exelixis Inc. $336.15 03/09/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766863
Principal investigator 1 PFIZER INC. $54.00 03/09/2022 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949814647
Principal investigator 1 Exelixis Inc. $8,378.57 03/07/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766857
Principal investigator 1 PFIZER INC. $2,472.50 03/05/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949824391
Principal investigator 1 PFIZER INC. $1,098.75 03/04/2022 Non-covered Recipient Entity
SMART Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 949824075
Principal investigator 1 PFIZER INC. $79,993.65 03/03/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949824359
Principal investigator 1 PFIZER INC. $7,036.20 03/03/2022 Non-covered Recipient Entity
SMART Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 949824715
Principal investigator 1 Exelixis Inc. $5,502.60 03/02/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766801
Principal investigator 1 Exelixis Inc. $765.00 03/02/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766817
Principal investigator 1 Exelixis Inc. $1,687.50 03/02/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766819
Principal investigator 1 Exelixis Inc. $2,801.25 03/02/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766821
Principal investigator 1 Exelixis Inc. $74.25 03/02/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766829
Principal investigator 1 Exelixis Inc. $535.50 03/02/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766831
Principal investigator 1 Exelixis Inc. $336.15 03/02/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766833
Principal investigator 1 Exelixis Inc. $1,350.00 03/02/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766835
Principal investigator 1 Exelixis Inc. $2,486.70 03/02/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766837
Principal investigator 1 ABBVIE INC. $94.50 03/01/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889778743
Principal investigator 1 ABBVIE INC. $4,291.31 03/01/2022 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 889778745
Principal investigator 1 MACROGENICS, INC. $26.00 02/28/2022 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 936956427
Principal investigator 1 GlaxoSmithKline, LLC. $4,358.00 02/18/2022 Non-covered Recipient Entity
MULTIPLE DOCTORS
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 943945395
Principal investigator 1 GlaxoSmithKline, LLC. $2,700.00 02/18/2022 Non-covered Recipient Entity
MULTIPLE DOCTORS
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 943945407
Principal investigator 1 PFIZER INC. $18.00 02/15/2022 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949814535
Principal investigator 1 Exelixis Inc. $39,139.33 02/11/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766395
Principal investigator 1 Exelixis Inc. $31,345.58 02/11/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766407
Principal investigator 1 Exelixis Inc. $74.25 02/09/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766355
Principal investigator 1 Exelixis Inc. $1,944.00 02/09/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766357
Principal investigator 1 Exelixis Inc. $1,020.60 02/09/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766379
Principal investigator 1 Exelixis Inc. $765.00 02/09/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766381
Principal investigator 1 Exelixis Inc. $4,437.00 02/09/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766383
Principal investigator 1 Exelixis Inc. $2,000.00 02/09/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766385
Principal investigator 1 Exelixis Inc. $1,910.25 02/09/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766387
Principal investigator 1 Exelixis Inc. $1,196.57 02/09/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766389
Principal investigator 1 MACROGENICS, INC. $567.88 02/08/2022 Non-covered Recipient Entity
START MIDWEST LLC
MGC018 WITH OR WITHOUT MGA012 IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 936956101
Principal investigator 1 MACROGENICS, INC. $241.65 02/08/2022 Non-covered Recipient Entity
START MIDWEST LLC
MGC018 WITH OR WITHOUT MGA012 IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 936956105
Principal investigator 1 MACROGENICS, INC. $398.72 02/08/2022 Non-covered Recipient Entity
START MIDWEST LLC
MGC018 WITH OR WITHOUT MGA012 IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 936956111
Principal investigator 1 PFIZER INC. $29,096.90 02/05/2022 Non-covered Recipient Entity
SMART Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 949824593
Principal investigator 1 Exelixis Inc. $9,815.63 02/04/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766195
Principal investigator 1 Exelixis Inc. $994.50 02/04/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766197
Principal investigator 1 Exelixis Inc. $1,630.80 02/04/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766199
Principal investigator 1 Exelixis Inc. $1,000.00 02/04/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766201
Principal investigator 1 Exelixis Inc. $300.00 02/04/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766203
Principal investigator 1 Exelixis Inc. $1,350.00 02/04/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766205
Principal investigator 1 Exelixis Inc. $833.96 02/04/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766207
Principal investigator 1 Exelixis Inc. $7,238.70 02/04/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766209
Principal investigator 1 Exelixis Inc. $25,583.31 02/04/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766215
Principal investigator 1 Exelixis Inc. $18.23 02/04/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766263
Principal investigator 1 Exelixis Inc. $112.05 02/04/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766265
Principal investigator 1 Exelixis Inc. $1,720.00 02/04/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766267
Principal investigator 1 Exelixis Inc. $2,930.85 02/04/2022 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766271
Principal investigator 1 PFIZER INC. $7,395.31 02/04/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949823935
Principal investigator 1 PFIZER INC. $881.00 01/28/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949823939
Principal investigator 1 AstraZeneca Pharmaceuticals LP $30,613.79 01/26/2022 Non-covered Recipient Entity
CANCER AND HEMATOLOGY
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation No dispute reported 06/30/2026 914589267
Principal investigator 1 MACROGENICS, INC. $53,668.88 01/26/2022 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 936955799
Principal investigator 1 MACROGENICS, INC. $22,837.82 01/26/2022 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 936955803
Principal investigator 1 MACROGENICS, INC. $37,682.41 01/26/2022 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 936955809
Principal investigator 1 PFIZER INC. $4,847.65 01/26/2022 Non-covered Recipient Entity
START Midwest
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 949814537
Principal investigator 1 PFIZER INC. $63.00 01/25/2022 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949813773
Principal investigator 1 PFIZER INC. $2,768.75 01/21/2022 Non-covered Recipient Entity
SMART Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 949823943
Principal investigator 1 PFIZER INC. $14,966.25 01/21/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949824529
Principal investigator 1 ABBVIE INC. $1,080.00 01/20/2022 Non-covered Recipient Entity
START MIDWEST LLC
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and is associated with poor prognosis and limited treatment options. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat advanced solid tumors No dispute reported 06/30/2026 889774571
Principal investigator 1 ABBVIE INC. $3,050.00 01/20/2022 Non-covered Recipient Entity
START MIDWEST LLC
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and is associated with poor prognosis and limited treatment options. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat advanced solid tumors No dispute reported 06/30/2026 889774597
Principal investigator 1 ABBVIE INC. $23,500.00 01/20/2022 Non-covered Recipient Entity
START MIDWEST LLC
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and is associated with poor prognosis and limited treatment options. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat advanced solid tumors No dispute reported 06/30/2026 889774599
Principal investigator 1 MACROGENICS, INC. $256.39 01/20/2022 Non-covered Recipient Entity
START MIDWEST LLC
MGC018 WITH OR WITHOUT MGA012 IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 936955661
Principal investigator 1 MACROGENICS, INC. $109.10 01/20/2022 Non-covered Recipient Entity
START MIDWEST LLC
MGC018 WITH OR WITHOUT MGA012 IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 936955667
Principal investigator 1 MACROGENICS, INC. $180.02 01/20/2022 Non-covered Recipient Entity
START MIDWEST LLC
MGC018 WITH OR WITHOUT MGA012 IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 936955671
Principal investigator 1 PFIZER INC. $47,543.69 01/11/2022 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 949823979
Principal investigator 1 PFIZER INC. $7,532.24 01/11/2022 Non-covered Recipient Entity
SMART Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 949824495
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $99,525.75 01/04/2022 Non-covered Recipient Entity
Start Midwest
Phase I II TIM3 FIH Monotherapy Nivo Combination in advanced solid tumors No dispute reported 06/30/2026 933190749
Principal investigator 1 Eli Lilly and Company $9,399.00 01/04/2022 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS LLC
A PHASE 1 MULTICENTER GLOBAL FIRST IN HUMAN STUDY OF THE CD73 INHIBITOR LY3475070 AS MONOTHERAPY OR IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES No dispute reported 06/30/2026 917835853